• CNMPA approves Agilent's PD-L1 Companion Diagnostic biospectrumasia
    October 08, 2019
    The assay is now approved as a companion diagnostic to identify patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (tumor proportion score [TPS] >1%) for first-line treatment with single-agent KEYTRU
PharmaSources Customer Service